...

Preclinical Toxicologists

As a preclinical toxicologist, your expertise is crucial during preclinical discovery, where you ensure the efficacy and safety of potential therapeutic compounds before they reach clinical trials. Our platform is designed to help you decipher target biology, resolve conflicting data, foresee potential safety concerns, and construct comprehensive experiments with ease and precision. With Causaly, uncover intricate toxicological profiles, identify hidden safety risks, and generate actionable insights faster than ever before. Join us in expediting preclinical development and transforming toxicity prediction, driving the future of safety pharmacology and contributing to breakthroughs in life sciences.

Scientist on computer

Decode Target Biology

Use AI to uncover unintended effects due to on-target or off-target activity hidden in the literature.

Comprehensive Understanding

Analyze scientific data extensively to enhance your understanding of target biology and its implications for safety and toxicology.

Hidden Connection Discovery

Uncover hidden connections within the data and reveal key insights about target biology that might otherwise remain unnoticed.

Efficiency Improvement

Navigate through the vast scientific data at speed and significantly accelerate your target safety assessment.

“I’ve used Multi-hop to find insights I wouldn’t otherwise find”
Senior Scientist
Top 20 Pharmacy
“Without Causaly, I would need to read 150 articles, compare the results and perform a trend analysis – a task that takes 2 weeks minimum. In Causaly, this is feasible in less than 5 minutes.”
Principal Scientist
Top 50 Pharmacy
“Causaly is now the first place I go to search the literature”
Senior Scientist
Top 50 Pharma
“Causaly has helped me find more and more potential targets that when I just used PubMed.”
Principal Scientist
Top 100 Pharma
“I’ve used Multi-hop to find insights I wouldn’t otherwise find”
Senior Scientist
Top 20 Pharmacy
“Without Causaly, I would need to read 150 articles, compare the results and perform a trend analysis – a task that takes 2 weeks minimum. In Causaly, this is feasible in less than 5 minutes.”
Principal Scientist
Top 50 Pharmacy
“Causaly is now the first place I go to search the literature”
Senior Scientist
Top 50 Pharma
“Causaly has helped me find more and more potential targets that when I just used PubMed.”
Principal Scientist
Top 100 Pharma

Preclinical Toxicologist Resources

Aiding Drug Repurposing Investigations with AI Featured Image
Anna Tzani • February 23, 2024

Aiding Drug Repurposing Investigations with AI

Drug repurposing offers a cost-effective and efficient pathway to discovery new therapeutic uses for existing treatments. AI can advance this process by rapidly analyzing large-scale biomedical data and scientific texts to identify drug-disease relationships, opening up avenues for treatments in unexplored indications.

Comparison of Safety Biomarkers for Chemotherapeutics Featured Image
Anna Tzani • February 9, 2024

Comparison of Safety Biomarkers for Chemotherapeutics

The identification and utilization of safety biomarkers plays a key role in mitigating toxicity risks and reducing costs in drug development, thereby accelerating the delivery of safe and effective drugs to patients. AI can streamline the identification of relevant biomarkers from the ever-growing biomedical literature, offering insights into drug resistance and toxicity.

AI-Powered Drug Discovery: Identifying Safety Red Flags Featured Image
Anna Tzani • January 30, 2024

AI-Powered Drug Discovery: Identifying Safety Red Flags

Unmanageable toxicity accounts for 30% of clinical drug development failures and can cause severe side effects and potential harm to patients. Download our report to see how AI-powered drug discovery can help mitigate late-stage clinical failures and market withdrawals.  

Uncovering the Mechanism of Action of Evolocumab against PAD Featured Image
Anna Tzani • January 12, 2024

Uncovering the Mechanism of Action of Evolocumab against PAD

Deciphering a drug’s MoA is crucial for making informed decisions in drug development, paving the way for the development of more targeted and effective therapeutic solutions. AI can revolutionize this process by facilitating knowledge discovery without bias, unveiling hidden drug-disease interactions.

Exploring the Cerebral Palsy Treatment Landscape Featured Image
Anna Tzani • November 1, 2023

Exploring the Cerebral Palsy Treatment Landscape

Cerebral palsy is an incurable neurological condition with profound motor function impact.  This blog explores the treatment challenges of cerebral palsy, focusing on central nervous system and musculoskeletal drugs, two mainstay medications to manage neurological symptoms, muscle plasticity and the related neuromuscular challenges.

Unlocking the Potential: Targeting RIPK1 for ALS Treatment Featured Image
Anna Tzani • October 5, 2023

Unlocking the Potential: Targeting RIPK1 for ALS Treatment

Amyotrophic Lateral Sclerosis (ALS) is a neuromuscular disease, affecting 12 individuals per 100,000 in the U. S. ALS is incurable, thus, the discovery of novel targets is paramount for improving treatment options. Using Causaly, we identified and assessed the potential of RIPK1 as a target for ALS.

Pharmacogenomic Insights: Temozolomide in Glioblastoma Featured Image
Anna Tzani • July 19, 2023

Pharmacogenomic Insights: Temozolomide in Glioblastoma

Pharmacogenomics is an emerging field that combines pharmacology and genomics to identify genetic factors influencing individual responses to medications. This innovative approach opens doors to more effective and personalized therapies, promoting patient safety and providing tailored treatment options.

Exploring the Latest Developments in Multiple Sclerosis: A 5-Year Overview Featured Image
Anna Tzani • May 30, 2023

Exploring the Latest Developments in Multiple Sclerosis: A 5-Year Overview

As we celebrate World MS Day on 30th May 2023, it’s a great opportunity to reflect on the significant strides that have been made in MS research over the past 5 years.

Causaly vs PubMed®: 2x as many relevant articles identified by Causaly using the same data Featured Image
Anna Tzani • November 18, 2020

Causaly vs PubMed®: 2x as many relevant articles identified by Causaly using the same data

: Medical Affairs, Regulatory and Pharmacovigilance experts are interested in identifying all the available evidence related to a drug’s safety profile. In order to accurately conduct a drug safety assessment, the relevance of results is pivotal, given the vast amount of data sources and time limitations.

Full-text vs Abstract advantage: Causaly identifies 3x as many relevant articles by machine-reading the full-text Featured Image
Dana Mavreli • October 31, 2020

Full-text vs Abstract advantage: Causaly identifies 3x as many relevant articles by machine-reading the full-text

Literature research is an ongoing, iterative process for all scientists. A literature review is a large task that can require 60–80 hours of focused effort for regulatory professionals (1). This includes scanning the medical literature to collect adverse events and analyzing the results.

Preclinical safety analysis using Artificial Intelligence on the example of Alzheimer’s Disease. Featured Image
Dana Mavreli • September 19, 2020

Preclinical safety analysis using Artificial Intelligence on the example of Alzheimer’s Disease.

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that currently produces dementia in 5.8 million U.S citizens. This number is projected to reach 13.5 million by 2050 highlighting the urgent need for means to prevent, delay the onset, slow the progression and improve the symptoms of AD (1).

Using AI to answer clinical questions: COPD Case Studies Featured Image
Yiannis Kiachopoulos • May 2, 2019

Using AI to answer clinical questions: COPD Case Studies

Chronic Obstructive Pulmonary Disease (COPD) describes a group of conditions which cause breathing difficulties, and includes chronic bronchitis and emphysema. The condition mainly affects older people who smoke and is typically managed by clinicians and other health professionals in a primary care setting.